Northern Trust
MRTX

Northern Trust’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Northern Trust’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-253,930
Closed -$14.9M – 4544
2023
Q4 		$14.9M Buy
253,930
+13,150
+5% +$739K ﹤0.01% 1822
2023
Q3 		$10.5M Buy
240,780
+26,022
+12% +$929K ﹤0.01% 1973
2023
Q2 		$7.76M Buy
214,758
+11,151
+5% +$459K ﹤0.01% 2233
2023
Q1 		$7.57M Buy
203,607
+9,574
+5% +$431K ﹤0.01% 2206
2022
Q4 		$8.79M Sell
194,033
-3,486
-2% -$226K ﹤0.01% 2095
2022
Q3 		$13.8M Buy
197,519
+5,782
+3% +$428K ﹤0.01% 1751
2022
Q2 		$12.9M Sell
191,737
-8,477
-4% -$539K ﹤0.01% 1833
2022
Q1 		$16.5M Buy
200,214
+1,784
+0.9% +$182K ﹤0.01% 1807
2021
Q4 		$29.1M Buy
198,430
+8,729
+5% +$1.36M ﹤0.01% 1509
2021
Q3 		$33.6M Sell
189,701
-42,959
-18% -$6.91M 0.01% 1396
2021
Q2 		$37.6M Sell
232,660
-242,310
-51% -$38.9M 0.01% 1381
2021
Q1 		$81.4M Sell
474,970
-20,102
-4% -$3.98M 0.02% 772
2020
Q4 		$109M Buy
495,072
+51,775
+12% +$11.2M 0.02% 602
2020
Q3 		$73.6M Sell
443,297
-19,081
-4% -$2.61M 0.02% 692
2020
Q2 		$52.8M Buy
462,378
+81,667
+21% +$7.92M 0.01% 852
2020
Q1 		$29.3M Buy
380,711
+34,083
+10% +$3.06M 0.01% 1142
2019
Q4 		$44.7M Sell
346,628
-9,987
-3% -$963K 0.01% 1101
2019
Q3 		$27.8M Buy
356,615
+57,731
+19% +$5.42M 0.01% 1412
2019
Q2 		$30.8M Buy
298,884
+6,818
+2% +$531K 0.01% 1370
2019
Q1 		$21.4M Buy
292,066
+17,591
+6% +$1.2M 0.01% 1628
2018
Q4 		$11.6M Buy
274,475
+1,444
+0.5% +$57.5K ﹤0.01% 1971
2018
Q3 		$12.9M Buy
273,031
+25,499
+10% +$1.42M ﹤0.01% 2100
2018
Q2 		$12.2M Buy
247,532
+187,191
+310% +$7.07M ﹤0.01% 2138
2018
Q1 		$1.85M Buy
60,341
+5,197
+9% +$144K ﹤0.01% 3142
2017
Q4 		$1.01M Buy
55,144
+1,743
+3% +$27K ﹤0.01% 3404
2017
Q3 		$625K Buy
53,401
+9,036
+20% +$52.3K ﹤0.01% 3535
2017
Q2 		$162K Sell
44,365
-127,669
-74% -$489K ﹤0.01% 3865
2017
Q1 		$894K Buy
172,034
+30,369
+21% +$166K ﹤0.01% 3379
2016
Q4 		$673K Sell
141,665
-4,477
-3% -$24.4K ﹤0.01% 3457
2016
Q3 		$966K Sell
146,142
-7,542
-5% -$40.1K ﹤0.01% 3350
2016
Q2 		$839K Buy
153,684
+10,937
+8% +$174K ﹤0.01% 3398
2016
Q1 		$3.06M Buy
142,747
+4,914
+4% +$110K ﹤0.01% 2738
2015
Q4 		$4.36M Buy
137,833
+10,893
+9% +$385K ﹤0.01% 2539
2015
Q3 		$4.37M Buy
126,940
+42,069
+50% +$1.27M ﹤0.01% 2525
2015
Q2 		$2.67M Buy
84,871
+15,340
+22% +$452K ﹤0.01% 2915
2015
Q1 		$2.04M Buy
69,531
+6,593
+10% +$155K ﹤0.01% 3109
2014
Q4 		$1.17M Sell
62,938
-1,034
-2% -$17.4K ﹤0.01% 3344
2014
Q3 		$1.12M Buy
+63,972
New +$1.19M ﹤0.01% 3380

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Northern Trust's MRTX Position: Q1 2024 in Review

Northern Trust sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 253,930 shares — an estimated $14.9M sold.

Northern Trust first reported a position in MRTX in Q3 2014 and held it in 38 quarters. The position peaked at $109M in Q4 2020. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Northern Trust reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Northern Trust sold 253,930 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $14.9M.
  • Northern Trust first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2014 and held it in 38 quarters.
  • Northern Trust's Mirati Therapeutics, Inc. Common Stock position peaked at $109M in Q4 2020.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Northern Trust's 13F filing for Q1 2024, filed 14 May 2024.